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ABSTRACT
The increase of diseases caused by Candida spp., and the treatment failures, has underscored the need for 
testing the susceptibilities to antifungal agents.  The commercial panel ATB® Fungus 2 was compared 
with the reference testing method of the European Subcommittee on Antifungal Susceptibility Testing 
of the Committee on Antimicrobial  Susceptibility Testing (AFST-EUCAST) for the evaluation of the 
susceptibility of isolates of Candida spp. to three agents.  The percentage of agreement was calculated 
based on the minimum inhibitory concentrations. There was a high correlation for AMB (100% қ = 1.0 
Bhapkar coefficient p = 1.0); while it was lower with azoles (85%, қ = 0.41, p = Bhapkar coefficient 
0.02 and 83.0%, қ = 0.15, Bhapkar coefficient p = 0.0006, respectively). The ATB® Fungus 2 and 
AFST-EUCAST are fully comparable methods for testing the susceptibility to AMB and to lesser extend 
comparable for ITR and FCA. 
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RESUMEN
El aumento de infecciones por Candida spp. y de las fallas en los tratamientos, suscitan la necesidad de pruebas 
de susceptibilidad. Se comparó la marca comercial ATB® Fungus 2 con la técnica estándar del Subcomité para las 
Pruebas de Sensibilidad Antifúngica de la Unión Europea, de la Sociedad de Microbiología Clínica y Enfermedades 
Infecciosas (AFST-EUCAST) para evaluar la susceptibilidad de aislamientos de Candida spp. a tres antifúngicos. 
Con base en las concentraciones inhibitorias mínimas se calculó el porcentaje de acuerdo.  La concordancia para 
anfotericina B (AMB) fue alta (100% қ = 1.0, Coeficiente de Bhapkarp = 1.0); para itraconazol (ITR) y fluconazol 
(FCA) fue inferior (85% қ = 0.41, Coeficiente de Bhapkarp =0.02 y 83.0 %, қ = 0.15, Coeficiente de Bhapkarp = 
0.0006, respectivamente).  Por lo tanto, ambas técnicas son comparables para la evaluación de la susceptibilidad a 
AMB; con los azoles el porcentaje de acuerdo es menor. 
Palabras clave: susceptibilidad antifúngica, Candida spp., ATB® Fungus 2, AFST-EUCAST.
INTRODUCTION
The incidence of diseases caused by various fungal 
pathogens has increased dramatically over the past 
few decades being Candida spp. the most common 
pathogen involved in these diseases.  This yeast causes 
a variety of diseases ranging from localized forms 
ofonychomycosis, vulvovaginitis andoropharyngeal 
candidiasis, to serious infections such asfungaemia 
and disseminated candidiasis, particularly, in immuno 
compromised patients 1, 2.   After the release of the first 
triazole antifungal and the lipid AMB formulations, 
several new antifungal drugs have become available. 
However, the increasing number of fungal infections 
and treatment failures in patients receiving long-term 
antifungal therapy has underscored the need for testing 
the susceptibilities of fungal pathogens to antifungal 
agents to guide the use of more appropriate therapies 1-3.
The Clinical and Laboratory Standards Institute 
(CLSI) and The European Subcommittee on 
Antifungal Susceptibility Testing of the Committee on 
Antimicrobial Susceptibility Testing (AFST-EUCAST) 
have developed the reference broth dilution methods 
M27-A3 4 and AFST-EUCAST 5 for drug susceptibility 
testing of Candida spp. respectively.  Unfortunately, the 
use of these reference methods is limited because they 
are time-consuming and labor-intensive 6.   A more rapid, 
reliable, reproducible, and locally available antifungal 
drug susceptibility testing method is desirable for 
routine application in clinical laboratories 7.  Different 
methods such as the ATB® Fungus 2 (BioMeriéux, 
Marcy-l’Etoile, France) have been commercially 
introduced.  ATB® Fungus 2 is a visible read panel 
designed to evaluate the susceptibility of Candida spp. 
and Cryptococcus neoformans to some of the most used 
antifungal compounds such as, AMB; 5 fluorocitosine, 
(5FC); fluconazole, (FCA) and itraconazole, (ITR). 
The aim of this study was to compare the performance 
of commercial panel ATB® Fungus 2 and the reference 
testing method AFST-EUCAST for the evaluation of 
the susceptibility of Candida spp. clinical isolates to 
ITR, FCA and AMB. 
MATERIALS AND METHODS
A total of 100 clinical isolates of Candida spp. obtained 
from individuals attending the Laboratory of Mycology 
of the School of Medicine at the University of 
Antioquia; The infectology laboratory of the University 
Hospital San Vicente de Paul and the clinical laboratory 
of Las Americas Clinic in Medellin, Colombia, were 
included in this study. Candida albicans isolates were 
identified by germ tube induction, growth at 42°C and 
chlamydospores formation on cornmeal agar (Beckton 
Dickinson, New Jersey, USA).  Other Candida species 
were identified by the commercial test for carbohydrate 
assimilation API-20CAUX (BioMérieux, l’Etoile, 
France).  Candida parapsilosis (ATCC-22019) and 
Candida krusei (ATCC-6258) strains were evaluated 
with ITR and AMB as quality control.
The commercial kit ATB® Fungus 2 was used following 
manufacturer instructions closely. The kit consists of 16 
pairs of cupules; one does not contain any antifungal 
agent (growth control) and the other pairs contain 
antifungal compounds previously prepared at the 
following concentrations: FCA (0.25µg/mL -128µg/
mL), ITR (0.5µg/mL-16µg/mL ) and AMB (0.5µg/
mL -16µg/mL).  Samples were resuspended in 5mL 
of API®NaCl 0.85% medium (BioMeriéux, Marcy-
l’Etoile, France) to obtain a turbidity equivalent to 2 
McFarland standard, and then 20µL of diluted sample 
was transferred into an ampule of ATB® Fungus 2 
medium. One hundred thirty five µL of this suspension 
were inoculated into each cupule, and finally incubated 
at 35oC for 24 hours. 
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Minimum inhibitory concentrations (MICs) were 
visually determined independently by 3 previously 
trained readers, comparing the growth of each cupule 
with the samples, with the growth in the control cupule 
and informed as follows: 4 = no reduction in growth, 
3 = slight reduction in growth, 2 = distinct reduction in 
growth, 1 = very weak growth, 0 = no growth. For AMB, 
the MIC corresponded to the lowest concentration 
producing complete growth inhibition (score “0”). 
Since there is the possibility of trailing for ITR and 
FCA, the MICs for these antifungal corresponded to the 
lowest concentration with which a score of 2, 1 or 0 was 
obtained.  The categorical classification of susceptibility 
by the ATB® Fungus 2 panel was carried out using 
the same CLSI M27-A2 MIC breakpoint categories 
according to the manufacturer’s instructions.  A strain 
was considered susceptible (S) for ITR and  FCA if the 
MICs were ≤ 0.125 µg/mL and ≤ 8µg/mL, susceptible 
intermediate (SI), if MICs were 0.25–0.50 µg/mL and 
16-32µg/mL, and resistant (R) if MICs were ≥ 1 µg/
mL and  ≥64µg/mL, respectively. These values are not 
formally defined for AMB by CLSI M27-A2 method, 
hence, we considered a strain S to this antifungal, if 
MICs were ≤2µg/mL, and R if MICs were >2µg/mL. 
Susceptibility testing for each isolate was conducted in 
triplicate and performed on three separate days.
For the AFST-EUCAST method, standards at the 
same concentrations with powders of ITR (Sigma 
Chemical Co, MO, USA), AMB (Sigma Chemical Co, 
MO, USA) and FCA (Pfizer Pharmaceutical Group 
New York, NY, USA) were prepared.  The inocula 
for microdilution plates were 0.5-2.5 x 105 CFU/mL. 
Minimum inhibitory concentrations were determined 
with a spectrophotometer (Bio-Rad, Hercules, USA) 
at 450 nm after 24 hours of incubation at 35°C.  For 
ITR and FCA, MICs were defined as the lowest drug 
concentration that inhibited 50% growth or more 
as compared with the control.  MIC for AMB was 
defined as the lowest concentration producing complete 
growth inhibition. According to breakpoint tables 
for interpretation of MICs (Version 6.1, valid from 
2013-03-11), the AFST- EUCAST has established the 
following categorical breakpoints: for AMB was MICs 
≤ 1µg/mL S and > 1µg/mL R. For ITR breakpoints have 
not defined, thereby; we used the same used for ATB® 
Fungus 2: for FCA: S = MICs ≤ 2µg/mL, SI 4µg/mL, 
and R > 4µg/mL, except for C. glabrata: S = MICs 
≤ 0,002µg/mL,SI > 0,002-32µg/mL, and R >32µg/
mL5-8.  Growth and sterility controls were included in 
each assay.  All isolates were evaluated in duplicate on 
three different days.
The geometric mean, range and median of MICs 
obtained by ATB® Fungus 2 and EUCAST for each 
antifungal compound were calculated for each species 
and determined if there was any statistical difference 
between the median of the MICs obtained by each 
method by the Mann Whitney test.  The overall 
percentage of agreement of MICs determined by ATB® 
Fungus 2 and AFST-EUCAST at different tolerances 
was also calculated.  A tolerance equals to zero means 
that MIC values of the sample tested by both methods 
were identical, whereas a tolerance equals to one, two 
or more, means that there was agreement between the 
results obtained by both methods if they only differ 
in one, two or more MIC values respectively.  The 
reproducibility of the results of the ATB® Fungus 2 test 
obtained independently by three readers was estimated 
using agreement percentage and Cohen’s Kappa index 
(қ).  Concordance between ATB® Fungus 2 and AFST-
EUCAST methods for categorical classification of 
Susceptible (S), Intermediate Susceptible (SI) and 
Resistant (R) strains was conducted stratifying by 
species.  Finally, an overall analysis including all the 
100 clinical isolates comparing the performance or the 
ATB® Fungus 2 to AFST-EUCAST  was conducted 
using the agreement percentage, қ index, and the 
Bhapkar coefficient of concordance 9 in order to test 
for all the marginal homogeneity (i.e. across all the 
categories simultaneously).  The criteria described 
by Fleiss 10 where a қ value less than 0.40 indicates 
poor agreement, 0.40 to 0.75 from acceptable to good 
agreement and higher than 0.75 excellent agreement 
was used. P value ≤ 0.05, was considered significant in 
all tests.  The R program version 2.9, (R Development 
Core Team (2008): a language and environment 
for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria.  (ISBN 3-900051-07-0) 
was used for all data analyses.  A significance level of 
0.05 was used in all tests.
RESULTS
Sixty percent of the clinical isolates was C. albicans, 
19% C. parapsilosis, 12% Candida tropicalis, 5% 
Candida glabrata, 3% Candida guilliermondii, and 
1% Candida famata. Nineteen percent of the isolates 
were obtained from urine, 22% from nails, 14% from 
abdominal secretion, 13% from oral mucosa, 8% from 
bronchial secretion, 7% from catheters, 6% from both 
blood and peritoneal fluids, 11% from other samples 
(tongue, vaginal fluid vitreous humour, pleural fluid, 
ear, cyst, thigh secretion, skin secretion).  The analysis 
of the reproducibility of the interpretation of the results 
of the ATB® Fungus 2 method showed that there was 
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good agreement between the 3 independent readers for 
the MICs values (84-100%, κ = 0.74).  Table 1 shows the 
geometric mean; range and median of MICs of AMB, 
FCA and ITR for 100 clinical isolates of Candida spp. 
evaluated by EUCAST and ATB® Fungus 2 methods.
In order to determine percentage of agreement of MICs 
value between ATB® Fungus 2 and AFST-EUCAST, 
the numerical comparison at different tolerances was 
conducted. Figure 1 shows the percentage of agreement 
between ATB® Fungus 2 and AFST-EUCAST methods 
for MICs at several tolerances for each antifungal 
agent.  At tolerance 0, the percentage of agreement for 
AMB was 60%, for FCA 35%, and for ITR 84%. At 
one tolerance, the percentage of agreement for AMB 
increases to 100%, for FCA at around 70% and for ITR 
at 87%.  The only major change at 2 tolerances it is 
observed for FCA.  The percentage of agreement for 
this antifungal increased to 89% with two tolerances 
but not major changes were observed for any of the 
antifungal tested to higher tolerances. 
The comparison between AFST-EUCAST and ATB® 
Fungus 2 methods for the categorical classification of 
susceptibility to AMB, FCA and ITR of isolates stratified 
by species are shown in Table 2.  The best agreement 
was obtained with AMB for all species included with 
both methods (100%; κ = 1).  However the agreement 
with the other two antifungal (FCA and ITR) was more 
variable and the percentage ranged from 20 to 28.6 
and the κ index from - 0.03 to 1.0, respectively.  The 
best agreement with both azoles was observed with C. 
famata, C. parasilopsisand C. albicans. Nonetheless 
there was difference in the percentage of agreement 
with the species C. glabrata and C. tropicalis (Table 2). 
†Mann-Whitney test
Candida spp 
Isolates
Table 1. Geometric mean, range and mean of MICs of amphotericin B, fluconazole and itraconazole for 100 clinical isolates of 
Candida spp. evaluated by ATB fungus 2 and EUCAST techniques
                                                                              MICs (mg/mL) 
                                 Geometric Mean     Range     Median  
                              N ATBF2®        T          ATBF2®   EUCAST           ATBF2®     Median P†
C. albicans  60         
AMB                 0.50        0.64          0.5-1   0.5-1  0.50      0.50           0.000
FCA                 0.47        0.33          0.25-32   0.25-64 0.50      0.25           0.000
ITR                 0.13        0.15          0.125-2   0.125-4 0.13      0.13           0.282
C. parapsilosis 19         
AMB                0.50        0.63          0.5-0.5   0.5-1  0.50      0.50           0.000
FCA                0.80        0.40          0.25-4   0.25-2  1.00      0.25           0.000
ITR                0.13        0.13          0.125-0.25   0.125-0.50.13 0.13      0.581
C. tropicalis 12         
AMB                0.51        0.81          0.5-1   0.5-1  0.50      1.00           0.000
FCA                1.36        6.11          0.25-64   0.25-64 1.00      32.00           0.211
ITR                0.19        0.51          0.125-4   0.125-4 0.13      0.31           0.003
C. glabrata 5         
AMB                0.50        0.87          0.5-0.5    0.5-1  0.50      1.00           0.000
FCA                2.41        18.38       0.25-32    4-64  2.00      16.00           0.001
ITR                0.32        0.79          0.125-4    0.25-4  0.25      0.50           0.007
C. famata 1         
AMB                0.50        0.50          0.5-0.5    0.5-0.5 0.50      0.50            -
FCA                0.32        0.25          0.25-0.5    0.25-0.25 0.25      0.25           0.505
ITR                0.13        0.13          0.125-0.125    0.125-0.125 0.13      0.13           -
C. guilliermondii 3         
AMB                0.50        0.63          0.5-0.5 0.5-1  0.50      0.50           0.076
FCA                2.00        2.94          0.5-4 1-8  4.00      4.00           0.330
ITR                0.32        0.20          0.125-1 0.125-0.25 0.25      0.25           0.412
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Table 2. Categorical agreement between EUCAST and ATB® fungus 2 techniques for susceptibility testing of amphotericin B, 
fluconazole and itraconazole for 100 clinical isolates of Candida spp. 
Antifungal / Candida spp  N Percentage agreement қ index
Amphotericin B    
 C. albicans                60        100.0                1.00
 C. tropicalis                12        100.0                1.00
 C. glabrata                  5        100.0                1.00
 C. parapsilosis                19        100.0                            1.00
 C. famata                 1        100.0                1.00
 C. guilliermondii                 3        100.0                1.00
 Candida  spp.                100        100.0                1.00
Fluconazole    
 C. famata                  1        100.0                1.00
 C. parapsilosis                 19         94.1                0.00
 C. albicans                 60         93.4                0.20
 C. tropicalis                 12         54.5                0.11
 C. guilliermondii                  3         33.3                0.00
 C. glabrata                  5         28.6                -0.03
 Candida  spp.                  100         83.0                0.15
Itraconazole    
 C. famata                  1        100.0                1.00
 C. albicans                 60          95.0                0.48
 C. parapsilosis                 19          94.1                0.00
 C. glabrata                  5          57.1                0.40
 C. tropicalis                 12          45.5                0.11
 C. guilliermondii                  3           33.3                0.00
 Candida  spp.                 100          85.0                0.41
N: number isolates     
                                                                              MICs (mg/mL) 
                                 Geometric Mean     Range     Median  
                              N ATBF2®        T          ATBF2®   EUCAST           ATBF2®     Median P†
C. albicans  60         
AMB                 0.50        0.64          0.5-1   0.5-1  0.50      0.50           0.000
FCA                 0.47        0.33          0.25-32   0.25-64 0.50      0.25           0.000
ITR                 0.13        0.15          0.125-2   0.125-4 0.13      0.13           0.282
C. parapsilosis 19         
AMB                0.50        0.63          0.5-0.5   0.5-1  0.50      0.50           0.000
FCA                0.80        0.40          0.25-4   0.25-2  1.00      0.25           0.000
ITR                0.13        0.13          0.125-0.25   0.125-0.50.13 0.13      0.581
C. tropicalis 12         
AMB                0.51        0.81          0.5-1   0.5-1  0.50      1.00           0.000
FCA                1.36        6.11          0.25-64   0.25-64 1.00      32.00           0.211
ITR                0.19        0.51          0.125-4   0.125-4 0.13      0.31           0.003
C. glabrata 5         
AMB                0.50        0.87          0.5-0.5    0.5-1  0.50      1.00           0.000
FCA                2.41        18.38       0.25-32    4-64  2.00      16.00           0.001
ITR                0.32        0.79          0.125-4    0.25-4  0.25      0.50           0.007
C. famata 1         
AMB                0.50        0.50          0.5-0.5    0.5-0.5 0.50      0.50            -
FCA                0.32        0.25          0.25-0.5    0.25-0.25 0.25      0.25           0.505
ITR                0.13        0.13          0.125-0.125    0.125-0.125 0.13      0.13           -
C. guilliermondii 3         
AMB                0.50        0.63          0.5-0.5 0.5-1  0.50      0.50           0.076
FCA                2.00        2.94          0.5-4 1-8  4.00      4.00           0.330
ITR                0.32        0.20          0.125-1 0.125-0.25 0.25      0.25           0.412
 
Figure 1. Percentage of agreement between ATB® Fungus 2 and EUCAST methods for MICs at several tolerances for each 
antifungal agent. Anfotericin B (AMB), Fluconazole (FCA), Itraconazole (ITR)
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                               AMB    ITR    FCA   
    
            S       SI    R  S SI R  S SI R  
           
S           100      0      0  82 0 7  82 6 8  
           
SI            0         0      0  1 1 5  1 0 2  
            
R            0         0      0  0 2 2  0 0 1  
  
            
Agreement 100    85    83   
  
қ index  1    0.41    0.15   
  
Bhapkar coefficient                                               -                                                           -   
      
p value  1    0.02                 0.0006   
      
 Amphotericin B (AMB), itraconazole (ITZ), Fluconazole (FCA)  
 
ATBF2 
EUCAST
Table 3. Overall categorical agreement between EUCAST and ATB® Fungus 2 methods for the susceptibility testing of 
amphotericin B, fluconazole and itraconazole for 100 clinical isolates of Candida spp. 
N: number isolates 
When overall categorical agreement between the two 
methods of susceptibility for AMB, FCA and ITR 
was calculated the agreement with AMB was 100 % 
(κ = 1.0) without significant difference between the 
methods when homogeneity across all the categories 
simultaneously was evaluated (Bhapkar test, P = 1.0) 
(Table 3).  The categorical analysis for ITR and FCA 
showed percentages of agreement lower than that 
observed with AMB (85.0 %, κ = 0.41 and 83.0%, қ 
index = 0.15, respectively) (Table 3). Also it was found 
significant difference in the coefficient of concordance 
(Bhapkar test p= 0.02 and p= 0.0006, respectively) 
(Table 3).
DISCUSSION
Clinical laboratories need alternative methods less 
expensive and laborious than the standard methods for 
testing the susceptibility to antifungal agents 6.  The 
ATB® Fungus 2 complies with these features to test 
the susceptibility of Candida spp. and C. neoformansto 
FCA, ITR, AMB and 5FC.  However the performance 
of this method in clinical settings has not been widely 
evaluated. In this study we compared this commercial 
kit with the reference method standard AFST-EUCAST 
with the antifungal most widely used in clinical 
practice.  Evaluation of 5FC was not included in the 
study since wide resistance of this antifungal precludes 
its use as a single agent.  Our results showed that the 
best agreement between AFST-EUCAST and ATB® 
Fungus 2 techniques for the categorical classification 
of susceptibility was observed with AMB.  Unlike, 
the agreement between both methods with the azoles 
was more variable. In contrast to AMB, the azoles are 
fungistatic and as consequence residual growth of yeasts 
could occur and prevent the accurate determination of 
the MIC.
On the other hand, the percentage of agreement and 
concordance between both tests, with azoles, for 
categorical classification of susceptibility of the isolates 
was dependent on the Candida species. However, the 
reduced number of samples for some of the species 
tested limits the possibility to make a clear conclusion. 
The differences observed in the results with azoles 
could have several explanations: (i) the established 
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cut-off points to determine the MICs are different in 
both techniques and the categories established for the 
ATB® Fungus 2 are broader than the established 50% 
growth inhibition of the AFST-EUCAST method. 
This is reflected in the fact that ATB® Fungus 2 
method classified as susceptible more isolates than the 
AFST-EUCAST.  Other plausible explanation for the 
differences is that there are isolates such as C. tropicalis, 
and C. glabratathat are subject to significant trailing 
growth, and that this may lead to the inaccuracy in MIC 
determination with the ATB® Fungus 2 11.  This may 
influence the poor concordance between tests when 
evaluating the susceptibility of the C. tropicalis isolates 
(12) to ITR (45.5% and қ = 0.11) and C. glabrata (8) 
to FCA (28.6% and қ = -0.03), this species showed 
decreased sensitivity or intrinsic resistance to FCA in 
other studies, even ATB-F3 6, 12, 13.
To date, few studies have been conducted comparing 
the correlation between ATB® Fungus 2 and other 
methods.  To our knowledge this is the first time that this 
method has been compared with the reference method 
AFST-EUCAST. Kantarcioglu (2001) compared the 
MIC values obtained by ATB® Fungus (version 1.0) 
with the reference method CLSI- M27A. This study did 
not include antifungals FCA and ITR, which does not 
permit comparison with our results 14.  More recently 
Torres-Rodriguez and Alvarado-Ramírez (2007), 
conducted a study that compared ATB® Fungus 2 
with the standard CLSI M27-A2 method and Sensititre 
Yeast One®.  They found that the overall agreements 
between methods were 94% and 99% for automated 
ATB® Fungus 2 and visual ATB® Fungus 2 readings, 
respectively and for Sensititre Yeast One the agreement 
was 91%. In this study, ITR presented the lowest 
concordance for Candida spp.15.  Eraso et al. (2008), 
compared ATB® Fungus 2 with SensititreYeastOne, 
the agreement between methods was assessed with 
133 Candida strains. The agreement (no more than two 
dilutions) of MIC results obtained by both methods was 
good (91.7-97.7%) for AMB, ITR, but lower for FCA 
(82.7%). On the other hand, the categorical agreement 
was good (93.2 to 98.5%) with 5-fluorocytosine and 
AMB, but lower with both triazoles (ITR and FCA) 
(72.9-75.9%) 12.  All these studies only used percentage 
of agreement to compare the tests, in contrast in our 
study κ index and Bhakpar were estimated which are 
more demanding than percentage of agreement. 
In conclusion, our results indicate that ATB® Fungus 
2 is comparable to AFST-EUCAST for the in vitro 
determination of susceptibility of Candida clinical 
isolates to AMB, and to a lesser extent to FCA and 
ITR.  However, we suggest that minor changes in the 
scale to determine the MICs or categorical breakpoints 
may improve the performance of the ATB® Fungus 2 
method to test the susceptibility to FCA.  Our results are 
in agreement with other studies that indicate that this 
commercial method could be a reliable procedure to 
evaluate susceptibility of Candida spp. isolates, though 
future studies should include a higher number of other 
than C. albicans species and previously characterized 
AMB resistant isolates in order to define the utility of 
this kit for detect AMB resistance in vitro. 
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